WallStreetZenWallStreetZen

NASDAQ: ARWR
Arrowhead Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Arrowhead Pharmaceuticals revenue was $829.45M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $256.5M, up 823.7% from last quarter. For the last reported fiscal year 2025 ending Sep 30, 2025, ARWR annual revenue was $829.4M, with 23,258.2% growth year-over-year.

ARWR past revenue growth

How has ARWR's revenue growth performed historically?

Company
23,258.15%
Industry
294.85%
Market
20.69%
ARWR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ARWR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ARWR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ARWR revenue history

Current Revenue
$829.4M
Current Earnings
-$1.6M
Current Profit Margin
-0.2%

Be the first to know when ARWR announces revenue.

ARWR Revenue History By Year

ARWR Yearly RevenueARWR RevenueARWR ChangeARWR Revenue Growth
2025-09-30$829.45M$825.90M+23,258.15%
2024-09-30$3.55M-$237.18M-98.52%
2023-09-30$240.74M-$2.50M-1.03%
2022-09-30$243.23M$104.94M+75.89%
2021-09-30$138.29M$50.30M+57.16%
2020-09-30$87.99M-$80.80M-47.87%
2019-09-30$168.80M$152.65M+945.67%
2018-09-30$16.14M-$15.27M-48.60%
2017-09-30$31.41M$31.25M+19,736.49%
2016-09-30$158.33k-$223.67k-58.55%
2015-09-30$382.00k$207.00k+118.29%
2014-09-30$175.00k-$115.27k-39.71%
2013-09-30$290.27k$143.39k+97.63%
2012-09-30$146.88k-$149.26k-50.40%
2011-09-30$296.14kN/AN/A
2010-09-30$0.00-$3.76M-100.00%
2009-09-30$3.76M$2.45M+188.38%
2008-09-30$1.30M$95.18k+7.88%
2007-09-30$1.21M$746.74k+161.88%
2006-09-30$461.28k-$129.40k-21.91%
2005-09-30$590.68k$394.38k+200.90%
2004-09-30$196.31kN/AN/A
2003-09-30$0.00N/AN/A

1 of 2

Arrowhead Pharmaceuticals Revenue FAQ

What was ARWR's revenue last quarter?

On Invalid Date, Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q3 2025 revenue of $256.47 million up Infinity% year over year. In the same quarter last year, Arrowhead Pharmaceuticals's revenue was $0.00.

What was Arrowhead Pharmaceuticals's revenue in 2025?

Arrowhead Pharmaceuticals's annual revenue for the twelve months ending Sep 30, 2025 was $829.45 million, a 23,258.15% increase year over year.

How much does Arrowhead Pharmaceuticals make in a day?

Based on Arrowhead Pharmaceuticals annual revenue for the past five years, ARWR makes an average of $797,398.36 per day.

What was Arrowhead Pharmaceuticals's annual revenue growth in the past year?

As of Q4 2025, Arrowhead Pharmaceuticals's revenue has grown 23,258.15% year over year. This is 22,963.3 percentage points higher than the US Biotechnology industry revenue growth rate of 294.85%. Arrowhead Pharmaceuticals's revenue in the past year totaled $829.45 million.

How much does Arrowhead Pharmaceuticals make in a year?

Arrowhead Pharmaceuticals's revenue by year for the past five years is:
  • Arrowhead Pharmaceuticals's revenue for the twelve months ending Sep 30, 2025 was $829.45 million, a 23,258.15% increase year over year.
  • Arrowhead Pharmaceuticals's annual revenue for Sep 30, 2024 was $3.55 million, a 98.52% decrease from 2023.
  • Arrowhead Pharmaceuticals's annual revenue for 2023 was $240.74 million, a 1.03% decrease from 2022.
  • Arrowhead Pharmaceuticals's annual revenue for 2022 was $243.23 million, a 75.89% increase from 2021.
  • Arrowhead Pharmaceuticals's annual revenue for 2021 was $138.29 million, a 57.16% increase from 2020.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.